GFS just logged one of its most explosive weeks in years. The stock surged 24% in a week to close at $74.04 — a 69% gain over the past month — driven by a Q1 earnings beat that forced a broad analyst rethink across the semiconductor coverage universe.
The catalyst is clear. GlobalFoundries reported Q1 adjusted EPS of $0.40 against a $0.34 estimate. Revenue of $1.634B edged past the $1.627B consensus. Q2 guidance bracketed the Street's forecasts too, with adj. EPS seen at $0.38–$0.48 versus a $0.40 estimate, and sales guided to $1.735B–$1.785B against a $1.743B consensus. None of those numbers are blow-out beats. But in a market starved for semiconductor visibility, even in-line guidance at the top is enough to move the needle hard.
The analyst reaction was both immediate and unusually coordinated. Seven firms raised price targets within 24 hours of the print. Susquehanna made the boldest call — upgrading to Positive with a $100 target, doubled from $50. Cantor Fitzgerald also upgraded, moving to Overweight with an $80 target. Needham's existing Buy saw its target lifted to $80 from $55. The major neutral houses moved too: UBS raised to $77, JPMorgan to $70, and Citigroup to $70. Only Morgan Stanley lagged the group, edging to $65 from $58 — and only Wedbush held firm at a $50 target without revision. The consensus remains a hold (8 buys, 8 holds, 1 sell), but target prices have repriced sharply, and the street's skew has tilted noticeably more constructive. The mean target of $75 now sits almost exactly on the current price — suggesting the Street, while more positive, doesn't yet have strong conviction on further near-term upside at these levels.
Short positioning tells a far less dramatic story, and that contrast is part of the setup. Short interest dipped to 2.2% of free float — a light read in absolute terms, and down roughly 27% from the mid-April peak when it briefly touched 3.1%. The sharp drop from around April 23 (when short shares fell from ~16.9M to ~12.4M overnight) appears linked to a float adjustment around the time of the earnings date, rather than a classic squeeze-driven cover. Borrow costs reinforce the unexcited nature of the short book: cost to borrow is a negligible 0.42%, down 12% on the week. Availability is ample. This is not a stock where short sellers are under structural stress. The ORTEX short score of 53.9 has fallen sharply from 61.8 a week ago — moving in the opposite direction to the share price, which is exactly what you'd expect when shorts are no longer leaning in.
Options positioning reflects the post-earnings recalibration but remains notably call-heavy. The put/call ratio of 0.43 sits above its 20-day mean of 0.34, with a z-score of roughly 1.2 — modestly more defensive than usual, though still squarely in call-dominated territory. The 52-week range for the PCR runs from 0.09 to 2.33, so current readings are far closer to the bullish end. The PCR has been drifting higher since the stock started its run in mid-April, which fits a pattern of investors adding hedges to protect recent gains rather than expressing fresh bearishness.
The ownership structure is dominated by Mubadala Investment Company, the Abu Dhabi sovereign wealth fund, which holds 76% of shares. That concentration limits the tradeable float considerably. Among institutional investors, FMR (Fidelity) is a distant second at 10.2%. Insider activity over the past 30 days has been uniformly in one direction: sell. The CLO, Chief Legal Officer, and several directors have been trimming regularly at prices ranging from $47 to $65. None of the transactions are large in absolute dollar terms (the biggest was a $233K sale by a director), and all appear to be part of routine scheduled programs. But the timing — selling into a stock that was already outperforming its semiconductor peers — is worth noting. Peer performance this week has been broadly strong: AMKR gained 7.5% on the week, POWI rose 16.8%, and DIOD added 16.4%, suggesting the wider sector is catching a bid. GFS outpaced them all regardless.
The bull case for GFS rests on silicon photonics — management's stated $1B revenue target by 2028 — along with automotive and IoT exposure that sits outside the most contested process nodes. The bear case is simpler: flat year-on-year revenue growth, intensifying competition from Chinese foundries at comparable nodes, and a highly capital-intensive business model that leaves thin margin for error. At a P/E of 36x and P/B of 3.2x — both materially richer than a month ago, when P/E sat around 22x — the valuation now prices in execution on the growth narrative. With analyst consensus clustered around the current price and a next investor event on the calendar for May 7, the question shifts to whether the Q1 beat is the start of a trend or a one-quarter relief rally in a stock that spent most of 2025 on the back foot.
See the live data behind this article on ORTEX.
Open GFS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
